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Background: Brain metastasis is an increasingly common complication for breast cancer patients; approximately
15– 30% of breast cancer patients develop brain metastasis. However, relatively little is known about how these
metastases form, and what phenotypes are characteristic of cells with brain metastasizing potential. In this study,
we show that the targeted knockdown of MMP-1 in breast cancer cells with enhanced brain metastatic ability not
only reduced primary tumor growth, but also significantly inhibited brain metastasis.
Methods: Two variants of the MDA-MB-231 human breast cancer cell line selected for enhanced ability to form
brain metastases in nude mice (231-BR and 231-BR3 cells) were found to express high levels of matrix
metalloproteinase-1 (MMP-1). Short hairpin RNA-mediated stable knockdown of MMP-1 in 231-BR and 231-BR3 cells
were established to analyze tumorigenic ability and metastatic ability.
Results: Short hairpin RNA-mediated stable knockdown of MMP-1 inhibited the invasive ability of MDA-MB 231
variant cells in vitro, and inhibited breast cancer growth when the cells were injected into the mammary fat pad of
nude mice. Reduction of MMP-1 expression significantly attenuated brain metastasis and lung metastasis formation
following injection of cells into the left ventricle of the heart and tail vein, respectively. There were significantly
fewer proliferating cells in brain metastases of cells with reduced MMP-1 expression. Furthermore, reduced MMP-1
expression was associated with decreased TGFα release and phospho-EGFR expression in 231-BR and BR3 cells.
Conclusions: Our results show that elevated expression of MMP-1 can promote the local growth and the
formation of brain metastases by breast cancer cells.
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Breast cancer is the most common malignancy in women
in the USA, and the second cause of cancer deaths after
lung cancer; metastasis is the major cause of morbidity
and mortality in breast cancer patients. Brain metastasis is
an increasingly common complication in breast cancer
patients, possibly a consequence of improvements in sys-
temic therapies. Approximately 15-30% of breast cancer
patients develop brain metastasis, with highest frequencies
in patients with “triple-negative” or basal tumors, and also
HER-2 positive tumors [1,2]. Investigations using patient
samples [3] and xenograft model systems of brain* Correspondence: hliu5@mdanderson.org; janprice11@gmail.com
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reproduction in any medium, provided the ormetastasis [4,5] are leading to improved understanding of
the pathobiology of brain metastasis.
Experimental models created to study the process of
brain metastasis were used to isolated variants of the
MDA-MB-231 human breast cancer cell line with
enhanced brain metastatic ability. These selected variants
have been used to identify and investigate the function of
various genes contributing to the development of brain
metastasis [6,7]. One gene, Matrix metalloproteinase-1
(MMP-1), was found to be highly expressed in two inde-
pendently isolated variants of this cell line. Matrix metal-
loproteinases (MMPs) are a family of zinc-dependent
endopeptidases which hydrolyze components of the extra-
cellular matrix (ECM). Physiologically, these enzymes play
a pivotal role in normal tissue re-modeling events such as
in embryonic development, angiogenesis, ovulation,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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over, high expression MMPs has been linked to several
pathologies, including cancer invasiveness. Evidence from
many clinical studies prompts further investigation of the
pathophysiologic role of MMP-1 in metastatic progres-
sion. Increased MMP-1 expression has been associated
with the incidence or invasiveness of various types of can-
cer, including colorectal, esophageal, pancreatic, gastric,
breast, and malignant melanoma [9-13]. Furthermore, ele-
vated MMP-1 expression in atypical ductal hyperplastic
tissues may serve as a marker for predicting which
patients will develop invasive breast cancer [14]. In
addition to functions in tissue remodeling, tumor progres-
sion, and metastasis through its proteolytic activities for
extracellular matrix (ECM) degradation, invasion, and
cytokine mobilization [15], MMP-1 may also promote
tumor invasion through proteolytic activation of the G
protein coupled receptor PAR1 [16]. MMP-1 has also
been shown to liberate signaling molecule precursors,
such as pro-TGFα, other EGF-like ligands and TGFβ from
cell surfaces or matrix [17-20]. This function may act to
drive autocrine or paracrine signaling within the tissue en-
vironment, such that MMP-1 can contribute to angiogen-
esis or osteoclast activation [21,22]. In contrast to these
well characterized functions of MMP-1 in tumor progres-
sion, its role in brain metastasis has received less
attention.
In this study, we show that the targeted knockdown of
MMP-1 in 231-BR and 231-BR3 cells not only reduced
primary tumor growth, but also significantly inhibited
the invasiveness of these two brain-seeking metastatic
breast cancer cells and attenuated formation of experi-
mental brain metastases. Inhibited MMP-1 expression
also decreased TGFα release and phospho-EGFR expres-
sion in 231-BR and 231-BR3 cells. These results suggest
that targeting MMP-1 and TGFα/EGFR signaling may




The 231-BR and 231-BR3 cells were derived from ex-
perimental brain metastases in nude mice injected with
the MDA-MB-231 human breast cancer cell line, as
reported previously [6,7]. The cells were maintained as
monolayer cultures in MEM supplemented with 5% FBS,
L-glutamine, MEM-vitamins, non-essential amino acid,
sodium pyruvate, and puromycin for transduced cells
(see below). Cell lines were validated by STR DNA fin-
gerprinting using the AmpFℓSTR Identifiler kit accord-
ing to manufacturer instructions (Applied Biosystems
cat 4322288). The STR profiles were compared to
known ATCC fingerprints (ATCC.org), to the Cell
Line Integrated Molecular Authentication database(CLIMA) version 0.1.200808 (http://bioinformatics.istge.
it/clima/) (Nucleic Acids Research 37:D925-D932 PMCID:
PMC2686526) and to the MD Anderson fingerprint
database. The STR profiles matched known DNA
fingerprints for MDA-MB-231 human breast cancer
cells.
Generation of knockdown cells
Stable shRNA-mediated knockdown was achieved
using SMARTvector shRNA lentiviral particles (with
puromycin as selection marker) (Thermo Scientific Co)
targeting the following sequences: sh1: GAGTACAACT
TACATCGTG; sh2: GAACTGTGAAGCATATCGA; sh3:
ACAGAATGTGCTACACGGA. A non-targeting control
SMART vector was transduced as a shRNA control.
shRNA lentiviruses were used to infect 231-BR and 231-
BR3 cells in the presence of 5 μg/mL polybrene. The
infected cells were selected with puromycin-supplemented
(1 μg/ml) MEM. Surviving cells were expanded and ana-
lyzed for MMP-1 mRNA expression and protein expres-
sion. In this study, sh3 shRNA showed minor effect on
knocking down MMP-1 (data not shown). shRNA lenti-
viruses targeting sh1 and sh2 sequences were used to
infected 231-BR and 231-BR3 cells. Two pools of selected
231-BR cells infected with shRNA lentiviruses targeting
sh1 sequence were named sh1a and sh1b. Two pools of
selected 231-BR3 cells infected with shRNA lentiviruses
targeting sh1 and sh2 sequences were named sh1 and sh2
respectively.
RNA-isolation and real-time RT-PCR
Total RNAs from different cell lines and xenograft
tumors were isolated with TriReagent (Sigma), treated
with TURBO DNAse (Ambion), and reverse transcribed
to cDNA with high capacity DNA archive reagents (Ap-
plied Biosystems) according to the manufacturer’s in-
struction. Real-time RT-PCR for MMP-1 was performed
in duplicates of each sample using a total reactive vol-
ume of 25 μl, which contained 1.25 μl of 20× Gene Ex-
pression Assay Mix (Applied Biosystems), 12.5 μl of
2 × TaqMan Universal PCR Master Mix (Applied Biosys-
tems) and 200 ng of cDNA template (diluted in RNase-
free water to 11.25 μl). After 2 min at 50°C and 10 min at
95°C, 40 cycles of 15 s at 95°C and 1 min at 60°C were
run. 18S in each sample was tested as intrinsic positive
control. Each plate included at least three “No
7Template Controls (NTC)”. Reactions were run
using the 7500 Real-Time PCR System (Applied Bio-
systems) and fluorescent data were converted into cycle
threshold (ΔCT) measurements.
ELISA
MMP-1 and TGFα protein expression levels were mea-
sured with an MMP-1 ELISA kit (Calbiochem Cat#
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system Cat# DY239) according to the manufacturers’
instructions. To prepare samples for ELISA, cells were
grown to 80% confluence with in medium with 0% or
5% FBS; supernatants from 24 h incubation were col-
lected, and concentrated 10-fold, using Amicon ultra-4
centrifugal filters. MMP-1 and TGFα amounts were cal-
culated as ng/ml and pg/ml protein, respectively, for dif-
ferent cell lines. For experiments using an MMP-1
inhibitor (EMD Chemicals, Gibbstown, NJ; cat# 444250)
cells were incubated for 24 h with 2 μM of the inhibitor.
Immunoblotting
Cells were harvested in RIPA lysis buffer, as described
previously [23]. Proteins from total cell lysates or ali-
quots of concentrated conditioned medium, were
resolved by the 7-12% Bis-Tris gradient gel, transferred
to the pure nitrocellulose membrane, blocked in 5%
non-fat milk or 5% BSA in TBS/Tween-20, and blotted
with the antibodies for MMP-1 (1:1000, Millipore Cat#
AB8105), phospho-EGFR (Tyr1068) (1:1000, Cell Signal-
ing Cat# 2236), total EGFR (1:2000, Upstate Cat# 06–
847), and β-actin (1:4,000, Sigma Cat# A2066).
In vitro migration and invasion assay
For Transwell migration assays, 2.5×104 cells were pla-
ted in the top chamber with the non-coated membrane
(24-well insert; pore size, 8 μm; BD Biosciences Cat#
354578). For invasion assays, 2.5×104 cells were plated
in the top chamber with Matrigel-coated membrane (24-
well insert; pore size, 8 μm; BD Biosciences Cat#
354480). In both assays, cells were plated in medium
without serum or growth factors, and medium supple-
mented with serum (5% FBS) was used as a chemo-
attractant in the lower chamber. The cells were
incubated for 24 h and cells that did not migrate or in-
vade through the pores were removed with cotton
swabs. Cells on the lower surface of the membrane were
fixed and stained with the Fisher HealthCare PROTO-
COL Hema 3 Manual Staining System (Fisher Scientific
Co.) and counted.
Tumorigenesis studies in mice
Six-week-old, specific pathogen-free athymic NCr-nu/nu
mice were purchased from Charles Rivers or from the
Animal Production Area of the National Cancer
Institute-Frederick Cancer Research and Development
Center (Frederick, MD). The care and use of laboratory
animals was in accordance with the principles and stan-
dards set forth in the Principles for Use of Animals
(NIH Guide for Grants and Contracts), the Guide for
the Care and Use of Laboratory Animals, the provisions
of the Animal Welfare Acts, and all procedures wereapproved by the Institutional Animal Care and Use
Committees.
Parental MDA-MB-231 cells, BR3, BR and pooled
stable knockdown cell lines containing the non-targeting
vector or the MMP-1 shRNA (5×106 cells/100 μl PBS)
were injected into the mammary fat pad of nude mice,
as described previously [23]. Tumors were measured
weekly and tumor volume was calculated using the for-
mula: volume = 0.5a2b (mm3), (a = smaller diameter, b =
larger diameter).
MMP-1 shRNA and control shRNA expressing BR
cells (shNTC, sh1a and sh1b) were injected into the left
heart ventricle of nude mice (1.75×105 cells in 0.1 ml
PBS), as described previously [24]. Mice were euthanized
under CO2 asphyxiation after 4 weeks, and brains were
excised and immediately frozen in ornithine carbamyl
transferase compound. Brain sections (10 μm thick) were
serially cut every 300 μm and processed for hematoxylin
and eosin (H&E) staining, and viewed using a micro-
scope with 5 × objective and ocular grid with 0.8 mm2
squares. Numbers of metastases were counted in 10 sec-
tions from each brain, with micrometastases classified as
lesions of < 300 μm, and large metastases as those that
measured > 300 μm in any dimension. Two separate
experiments were performed, and the data were com-
bined for statistical analysis.
MMP-1 shRNA and control shRNA expressing BR3
cells (shCtr and sh1) were injected into tail veins of nude
mice at the density of 2.5×105 in 0.1 ml PBS for each cell
line. Mice were sacrificed after 9 weeks and lungs were
excised and fixed in formalin and processed for H&E
staining. Lung metastases were counted on one H&E
stained lung section from each mouse and classified into
small (diameter < 0.5mm), medium (diameter 0.5-1.5 mm)
and large (diameter > 1.5mm) metastases.Immunohistochemistry
Mammary fat pad tumors and lungs were collected from
each mouse at necropsy, and fixed in 10% buffered for-
malin. Tissues were paraffin embedded, sectioned, and
stained with H&E, MMP-1 (Epitomics Cat# 1973–1) and
Ki-67 (Epitomics Cat# 4203–1). Brain frozen sections
were stained with H&E and Ki-67 (Thermo/lab Vision
Cat# RB-90-43) staining.Statistical analysis
Data are presented as mean ± SEM. Student’s t test (two
tailed) was used to compare two groups (P < 0.05 was
considered significant) unless otherwise indicated (Fish-
er’s exact test and ANOVA with Dunnett’s multiple
comparison test). Microsoft Excel and Graphpad Prism
software were used for statistical analyses.
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Stable expression of MMP-1 shRNAs knocks down MMP-1
expression in breast cancer cells
Two variants of the MDA-MB-231 breast cancer cell
line, 231-BR and 231-BR3, were established independ-
ently by two research groups, and have been shown to
have enhanced brain-metastasizing potential [6,7].
Microarray analyses were performed by the Steeg labora-
tory to identify common differentially expressed genes;
altered expression of 26 genes was seen in both brain
metastasis-derived variants compared with the parental
cell line. Of these, MMP-1 was the most highly
expressed gene. The expression of MMP-1 gene in 231-

















































































































Figure 1 MMP-1 shRNAs specifically inhibit MMP-1 expression in BR3
Compared with MDA-MB-231 parental cells and variants LC3 (selected from
BR cells showed high levels of MMP-1 expression. This data shown are repr
down MMP-1 mRNA level in BR3 and BR cell lines, compared with shCtr an
performed in triplicate. C, ELISA assays and D, western blotting showed tha
reduced in BR3 and BR expressing MMP-1 targeting shRNA. These experim
expression of MMP-2, TIMP-1, TIMP-2 and VEGF in sh1 cells. This data showincreased 36-fold compared with parental MDA-MB-231
cells (data not shown). The increased expression was
confirmed using real time PCR measurements
(Figure 1A). Included in the comparison was a variant
selected from experimental lung metastases (231-LC3
[6]), which did not express increased MMP-1; this sug-
gested that the increase in expression is not a conse-
quence of selection of cells from xenografted tumors in
general, but may be linked to the formation of experi-
mental brain metastases.
Silencing MMP-1 expression in 231-BR and 231-BR3
cells was undertaken to define the role of MMP-1 in
brain metastasis. Three different sequence-targeting















































































































and BR cells. A, real-time PCR quantification of MMP-1 mRNA levels.
experimental lung metastases), the brain metastasis-derived BR3 and
esentative of 3 independent experiments. B, MMP-1 shRNAs knocked
d shNTC cells expressing control shRNA. This experiment was
t MMP-1 protein levels in conditioned media were significantly
ents were performed in triplicate. E, MMP-1 shRNA did not affect the

































































Figure 2 MMP-1 suppression inhibits invasion ability but not
migration ability of 231-BR3 and 231-BR cell lines in vitro. A,
231-BR cells, 231-BR3 cells, control shRNA and MMP-1 shRNA
expressing cells were tested for their ability to migrate to 5% FBS in
the lower chamber of Transwell chambers. 2.5×104 cells were
seeded in the migration chamber in serum-free medium. Migrated
cells were fixed and counted after 24 h. MMP-1 knockdown in BR
and BR3 cells did not affect cell migration ability. The data shown
were combined from 5 independent experiments. B, control shRNA
and MMP-1 shRNA expressing BR and BR3 cells were tested for
ability to invade across a Matrigel-coated membrane in response to
5% FBS in the lower chamber. 2.5×104 cells were seeded in the
invasion chamber in serum-free medium. Invaded cells were fixed
and counted after 24 h. Asterisks indicate significant differences
(P < 0.05) between control shRNA expressing cells and MMP-1
shRNA expressing cells. The data shown were combined
from 5 independent experiments.
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Cells were selected with puromycin-supplemented
(1 μg/ml) MEM. Surviving cells were expanded and
analyzed for MMP-1 mRNA expression and protein
expression. Stably MMP-1 knockdown cell lines sh1,
sh2 (231-BR3) and sh1a, sh1b (231-BR) showed decreased
MMP-1 mRNA expression (Figure 1B). ELISA and immu-
noblots of culture supernatants showed that secreted
MMP-1 protein was reduced in samples collected from the
shRNA-expressing cell lines compared with control cell
lines shCtr (231-BR3) and shNTC (231-BR), respectively
(Figure 1C, D). Cell lines transfected with lentivirus
with the sh3 sequence showed no reduction in MMP-1
expression, and were not used for further experiments.
The specificity of MMP-1 shRNA was determined by
measuring the relative expression of MMP-2 and MMP-7;
no expression of the latter was detected. Transduction
with shRNA to MMP-1 did not substantially alter expres-
sion of MMP-2, TIMP-1, TIMP-2 or VEGF (Figure 1E
shows data for 231-BR3 transfectants; the same experi-
ments with 231-BR transfectants yielded similar results).
MMP-1 suppression inhibits invasion ability of breast
cancer cells in vitro
Recent studies showed that pericellular degradation of
substrates by membrane-tethered MMPs is a key step
for promoting cell invasion [20]. Having found elevated
expression of MMP-1 in 231-BR cells and 231-BR3 cells,
we sought to test whether MMP-1 shRNA could inhibit
their invasiveness. First we tested if MMP-1 knockdown
affected the motility of 231-BR and 231-BR3 cells. The
results showed that MMP-1 knockdown in BR and BR3
cells did not affect cell migration ability (Figure 2A).
Then control shRNA and MMP-1 shRNA expressing BR
and BR3 cells were tested for ability to invade across a
Matrigel-coated membrane in response to 5% FBS in the
lower chamber. The result indicated that there was a sig-
nificant reduction (P < 0.05) in the invasive properties of
MMP-1 shRNA expressing cells compared with control
shRNA expressing cells (Figure 2B). Taken together,
these observations suggested that MMP-1 function is
required for in vitro invasiveness but not for motility of
these metastatic cells.
Stable knockdown of MMP-1 expression inhibits local
tumor growth
MTT assays were used to analyze if MMP-1 reduction
affects breast cancer cell proliferation in vitro. The result
showed no difference in proliferation between control
and MMP-1 knockdown cells (Additional file 1). To test
whether MMP-1 knockdown affected tumor growth
in vivo, we injected MMP-1 shRNA expressing cells and
control shRNA expressing cells into the mammary fat
pads of nude mice. After 6 weeks, the tumors of MMP-1knockdown cell lines sh1 and sh1b were significantly
smaller than those of the control lines shCtr and shNTC
(Figure 3A). Real-time PCR quantification using RNA iso-
lated from tumor tissues confirmed the continued silen-
cing of MMP-1 in vivo (Figure 3B). Immunohistochemical














   
   







































Figure 3 Stable knockdown of MMP-1 expression inhibits local tumor growth. A, each cell line was injected into mammary fat pads of
nude mice (5×106 cells per mouse). Each group includes five mice. Asterisks indicate that the tumors of MMP-1 knockdown cell line sh1 grew
significantly slowly than the control cell line shCtr (P < 0.05, t-test) and the tumors of MMP-1 knockdown cell lines sh1a and sh1b grew
significantly slowly than those of the control cell line shNTC (P < 0.01, ANOVA Dunnett’s Multiple comparison test). B, real-time PCR quantification
of MMP-1 mRNA levels of tumors showed a significant reduction in tumors of sh1 cells compared with shCtr tumors. C, representative MMP-1
immunohistological staining of tumor sections showing reduced staining in sh1 and sh1b tumors.
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with tumors of the control cell lines (Figure 3C).
The incidence of tumor formation by the MMP-1
knockdown cells was moderately reduced compared with
the control cell lines (231-BR-shNTC, 100% tumor take
compared with 231-BR-sh1b, 67% tumor take; 231-BR3-
shCtr, 80% tumor take, compared with sh1, 60%), al-
though the differences were not statistically significant,
using Fisher’s Exact test (Additional file 2). To determine
whether MMP-1 knockdown affected cell proliferation
in breast tumor, proliferation marker Ki-67 staining was
performed on sections of breast tumor. The result
showed no difference in proliferation between control
and MMP-1 knockdown tumors (Additional file 3).
Taken together, although MMP-1 was not essential for
tumor initiation in the mammary fat pad and its reduction
has no effect on proliferation of breast cancer cells
in vitro, silencing expression of MMP-1 reduced tumor
growth in vivo.
Inhibition of MMP-1 in 231-BR cells attenuates
brain metastasis
A key question was whether MMP-1 could promote brain
metastasis. To determine whether MMP-1 knockdown
affected brain metastasis, 1.75×105 MMP-1 knockdowncells (sh1a, sh1b) and control cells (shNTC) cells were
injected into the left heart of nude mice, as described pre-
viously [24]. Mice were sacrificed 4 weeks later and brains
removed for analysis of metastasis formation. The sh1a
and sh1b cells formed fewer large metastases (reduced by
43% and 80.5%, respectively) and fewer total metastases
(reduced by 31% and 43%, respectively) compared with
the control shNTC cells (Figure 4B, A).
To determine whether MMP-1 knockdown affected cell
proliferation in brain metastases, we performed immuno-
histochemistry with the Ki-67 proliferation marker. We
found that the brain metastases of the shNTC cells had
significantly more Ki-67 positive cells that the brain me-
tastases of the MMP-1 knockdown cells (Figure 4C, D).
Hence, MMP-1 knockdown reduced the proliferation of
metastatic breast cancer cells in the brain.
Inhibition of MMP-1 in 231-BR3 cells attenuates
lung metastasis
We next injected MMP-1 shRNA expressing 231-BR3
cells (sh1) and control shCtr cells into the tail veins of
nude mice. Mice were sacrificed and lung sections were
analyzed after 9 weeks. Numerous metastatic nodules
were observed in the lungs of mice inoculated with con-
trol shCtr cells, but fewer were found in the lungs of
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Figure 4 MMP-1 knockdown in 231-BR cells attenuates brain metastasis. MMP-1 shRNA expressing 231-BR cells, sh1a and sh1b, and control
shNTC cells were injected into the left heart of nude mice, 1.75×105 cells per mouse. Each group includes ten mice. Mice were sacrificed after 4
weeks and the number of experimental metastases scored in serial brain sections. A, Representative H&E staining of brain sections. Arrows
indicate metastatic foci. B, The sh1a and sh1b cells formed fewer large metastases and total metastases compared with the control shNTC cells.
The data were combined from two independent experiments, shown as the mean and SEM of metastases scored in serial sections. Asterisks
indicate that sh1b cells formed significantly fewer large and total metastases compared with shNTC cells (P = 0.002, P = 0.0067 respectively,
ANOVA Dunnett’s Multiple comparison test). C, Ki-67 stained sections of brain metastases formed by injection of 231-BR control cells and MMP-1
knockdown cells and D, comparisons of Ki-67 positive cells in brain metastases. Significantly fewer Ki-67 positive cells were found in brain
metastases of sh1a (P = 0.022) and sh1b (P = 0.011, Student’s t-test) compared with metastases of shNTC cells.
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metastatic foci, lung sections were stained with H&E,
and the numbers of lung metastatic foci were counted
and measured. Lung metastases were categorized into 3
groups based on the size; less than 500 μm of diameter
was termed small, 0.5-1.5 mm, medium and greater than
1.5 mm of diameter, large. Fisher’s Exact test showed a
significant difference in the incidence of large metastases
in the lungs of mice injected with sh1 cells compared to
samples from mice injected with shCtr cells (P < 0.05)
(Figure 5B). This result further confirmed that MMP-1
expression promotes the development of metastases.
Stable knockdown of MMP-1 expression is associated
with reduced TGFα release and activation of EGFR
These data showed that reducing MMP-1 expression not
only reduced local mammary tumor growth, but alsoattenuated the metastatic ability of breast cancer cells. In
vitro, MMP-1 knockdown reduced the invasiveness of
breast cancer cells. Many reports have shown that MMP-1
can promote tumor growth and metastasis through cata-
lyzing extracellular matrix and by promoting angiogenesis
[21]. In addition, MMP-1 can activate or release growth
factors to promote metastasis [17,19,22].
To test if release of TGFα was linked to MMP-1 expres-
sion in the brain metastasis-derived variants of MDA-MB-
231, we measured both MMP-1 and TGFα concentrations
in culture supernatants of MMP-1 shRNA expressing cells
and control cells by ELISA (Figure 6A). The results
showed lower concentrations of TGFα in samples from
the MMP-1 knockdown cell lines. The addition of an
MMP-1 inhibitor in further experiments confirmed that
MMP-1 activity can modulate levels of TGFα in culture
supernatants of the breast cancer cell lines (Figure 6B). To






































Figure 5 MMP-1 knockdown in BR3 cells attenuates lung
metastasis. MMP-1 shRNA expressing 231-BR3 cells sh1 and control
shCtr cells were injected into the tail veins of nude mice at the
density of 2.5×105/100 μl PBS. Each group includes ten mice. Mice
were sacrificed and lung sections were analyzed after 9 weeks.
A, representative H&E staining of lung sections. Arrows indicate
metastatic foci. B, for each group, total lung metastatic foci were
counted. Fisher’s exact test showed a significant difference between
the numbers of lung foci in the sh1 group compared to shCtr
group (P < 0.05).
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Figure 6 Stable knockdown of MMP-1 is associated with
reduced TGFα in culture supernatants. A, MMP-1 and TGFα
protein levels in conditioned media were measured by ELISA. Cells
were cultured in MEM with 5% FBS to 80% confluence. Supernatants
were separated and concentrated, and MMP-1 and TGFα protein
concentrations were measured by ELISA. Asterisks indicate significant
differences (P < 0.05) in TGFα in culture supernatants from control
shRNA expressing cells compared with MMP-1 shRNA expressing
cells. This data shown are representative of 3 independent
experiments. B, TGFα concentrations in conditioned media were
measured by ELISA after 24 h incubation with MMP-1 inhibitor at
2 μM, in serum free medium. This data shown are representative of
3 independent experiments. C, Immunoblotting for phospho-EGFR,
total EGFR and β-actin protein levels in each cell line cultured in
culture medium with 5% FBS. This experiment was performed in
triplicate.
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to an off-target effect of the shRNA to MMP-1, real-time
RT-PCR measurements of TGFαwere performed. The
results showed no substantial change in expression of
TGFα between the control and MMP-1 knockdown cell
lines (Additional file 4).
As TGFα is a ligand for EGFR, we next measured
phospho-EGFR expression in MMP-1 knockdown cells
and control cell lines (Figure 6C). In the MMP-1
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were lower than in control cells (shCtr and shNTC). The
results demonstrated that active MMP-1 proteolysed la-
tent TGFα to generate active TGFα, leading to an acti-
vated EGFR signal pathway, thus linking MMP-1 and the
EGFR signaling pathway in metastatic breast cancer cells.
Discussion
In this report we provide evidence that elevated expres-
sion of MMP-1 contributes to the brain colonizing po-
tential of human breast cancer cells in xenograft models
of cancer progression.
Members of the MMP family play important roles in
normal and malignant processes. Their functions in inva-
sion and metastasis have been associated primarily with
degradation of ECM components [18,25,26]. In recent
years, however, it has become increasingly clear that
MMP substrates extend to many non-matrix extracellular
and membrane-bound proteins, including protease pre-
cursors and inhibitors, cytokines, latent growth factors,
growth factor-binding proteins, and adhesion molecules
[17]. Understanding how MMP-1 and other members of
the MMP family promote metastasis, in part by altering
the signaling milieu in the tissue microenvironment colo-
nized by disseminating cells may be crucial for developing
more effective therapies for metastatic cancer.
Our study shows that MMP-1 is highly expressed by
the brain metastasis-derived variants of the human
MDA-MB-231 breast cancer cell line; this supports find-
ings reported by others [4]. What drives the elevated
expression remains to be established; the 231-BR and
231-BR3 variants have constitutive activation of STAT3,
which has been linked to elevated expression of various
genes, including VEGF, cyclin D and survivin [27]. Tran-
scriptional regulators of MMP-1 in cancer cells include
STAT3 [28] and members of the AP-1 family of tran-
scription factors [29].
Reducing the expression of MMP-1 with shRNA atte-
nuated tumor growth in the mammary fat pads and
reduced invasion through matrix-coated filters of the
231-BR and 231-BR3 cells, similar to the findings of
other investigators using non-selected MDA-MB-231
cells [30,31]. Metastatic lesions formed by cells expres-
sing shRNA to MMP-1 in the lungs or brains, from i.v.
or intra-cardiac injections, respectively, were smaller and
fewer than those formed by the control cells. Without
using a method to follow the fate of cells after injection
into mice we cannot discern whether the reduction in
metastasis number is due to impaired arrest and extrava-
sation, or reduced proliferation in the metastatic site; the
data would support a combination of these possibilities.
MRI has been used to document the fate of MDA-MB-
231-BR cells tagged with iron oxide particles in the
brains of nude mice after intra-cardiac injection. Themajority of the cells were rapidly eliminated, and only a
small fraction of the initial inoculum formed actively
growing metastases [32]. Fitzgerald et al. [33] reported
high proliferation rates of brain metastases of this cell
line, as we also found for metastases of control shRNA-
expressing cells, while significantly fewer cells in brain
metastases of the MMP-1 silenced cell lines were prolif-
erating (Ki67-positive).
Our data show that MMP-1 can regulate the levels of
TGF-α in culture supernatants of the MDA-MB-231-BR
and -BR3 cells, which in turns affects activity of EGFR in
the cancer cells. The activation of EGFR can regulate a
wide variety of cellular functions [34,35]. One related to
brain metastasis is the recent report of EGF promoting
heparanase function and Topoisomerase I localization in
brain metastasizing breast cancer cells [36]. Treatment
with cetuximab, a humanized antibody to EGFR, reduced
transmigration through a simulated blood–brain barrier
and extended survival of mice injected with brain-
colonizing breast cancer cells [4]. MDA-MB-231-BR cells
express phosphorylated EGFR in vivo, and treatment with
lapatinib, a small molecule tyrosine kinase inhibitor of
EGFR and HER2, significantly reduced the numbers of
large brain metastases formed by these cells [37]. The
TGF-α released around MMP-1 expressing cells may also
have paracrine functions in the brain microenvironment,
including induction of angiogenesis and neurogenesis [38],
and activation of astrocytes in response to injury [39,40].
Reactive microglial and astrocytic responses to brain
metastases have been reported in studies using the MDA-
MB-231-BR model [33] and other experimental brain
metastasis models [41,42], resembling the peritumoral
changes seen in clinical brain metastases [43]. These
responses may promote the proliferation and survival of
the metastatic cells [33,41,44,45]. Reactive astrocytes have
neuroprotective functions, which may be exploited by
cancer cells; co-culture of astrocytes with brain metastatic
cells protected the latter from chemotherapy-induced
apoptosis, an effect dependent upon gap-junction commu-
nications between the different cell types [5,42].
While not explored further in this study, MMP-1 acti-
vation of protease-activated receptor 1 (PAR1) may also
contribute to the process of brain metastasis. Protease-
activated receptors are members of the G protein
coupled receptor family that are activated upon cleavage
of an N-terminal tethered ligand. Thrombin and MMP-1
both activate PAR1, but MMP-1 is reported to cleave the
tethered ligand at a unique site [46]. PAR1 expression
on breast cancer cells has been associated with a high
metastatic potential, and inhibiting the downstream sig-
nals from PAR1, using a small molecule inhibitor, sup-
pressed Akt-mediated survival pathways, and attenuated
tumor growth and experimental lung metastasis [47].
The brain metastatic variants of MDA-MB-231 maintain
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original cell line (Liu and Price, unpublished). PAR1 is
also expressed by other cell types present in the brain
microenvironment, including endothelial cells [48] and
astrocytes; activation of PAR1 on the latter can trigger
astrogliosis [49].
Conclusions
Tumor metastasis is a complex and highly regulated
process involving multiple tumor-host interactions,
mediated by various host- and tumor-derived factors
[50,51]. Our results, together with those from many
other studies, suggest that blocking the actions of MMP-
1 should theoretically prove beneficial in the treatment
of invasive and metastatic cancers. However, clinical
trials with broad-spectrum MMP inhibitors for various
cancers have failed to improve patient outcome and
often produced adverse events, including dose-limiting
joint toxicity [52,53]. As more details of functions of
MMP-1 in metastasis to the brain and other organs are
defined, this information may be useful for decisions of
clinical management. MMP-1 has been proposed as a
biomarker for breast cancer [14,53]; understanding its
role in activation of the TGFα/EGFR signal pathway may
lead to the use or development of additional targeted
agents to suppress this axis, and result in improved
treatments for metastatic breast cancer.
Additional files
Additional file 1: Parental MDA-MB-231, BR3, BR and shRNA
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BR3 groups.
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transfected variant cells were injected into mammary fat pads of
nude mice at an inoculum of 5X106 cells/0.1 ml. After 7 weeks, mice
were sacrificed and tumor formation was compared. Statistical
comparison by Fisher’s exact test is expressed as p > 0.05 for both BR
and BR3 groups.
Additional file 3: Ki-67 staining was performed on sections of
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images and B, quantification of Ki-67 staining.
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